Company officials at NuVasive discuss earnings results for Q3 2013. NuVasive posted profits of $7.5 million, or 16¢ per share, on sales of $169.2 million for the 3 months ended Sept. 30.
NuVasive more than triples its 3rd-quarter profits and boosts its sales and earnings outlook for the rest of the year.
NuVasive Inc. (NSDQ:NUVA) could be a big gainer today after the medical device company said yesterday that it more than tripled its 3rd-quarter profits, bested Wall Street's earnings expectations and boosted its sales and earnings outlook for the balance of 2013.
Spinal devices maker NuVasive debuts its new XLIF Decade posterior fixation system in the U.S.
NuVasive Inc. (NSDQ:NUVA) introduced a new implant to be used with its XLIF spinal fusion procedure in the U.S., the XLIF Decade plate.
The device is designed to provide surgeons with an option for a single-approach XLIF (eXtreme Lateral Interbody Fusion), NuVasive's alternative to traditional spinal fusion procedures.
NuVasive introduces its new Precept posterior fixation system in Japanese patients, hoping to use the device to break into the country's spinal market.
California medical device company NuVasive Inc. (NSDQ:NUVA) debuted its Precept spinal implant in Japan, treating the 1st patients with the posterior fixation system.
A swath of law firms are looking to join a class action lawsuit filed against NuVasive after the company revealed a federal investigation into its Medicare and Medicaid billing practices.
NuVasive moves to a larger London facility as the spinal devices maker aims for a larger share of Northern European markets.
Spinal surgery devices maker NuVasive Inc. (NSDQ:NUVA) is heading to a new U.K. office as the company anticipates taking more share in markets across Northern Europe.
NuVasive swings to 2nd-quarter losses, partly on increased royalties due to rival Medtronic in their ongoing patent dispute, as it reveals a probe by the Office of the Inspector General for the U.S. Health & Human Services Dept.